期刊文献+

常染色体显性多囊肾病药物治疗进展 被引量:6

原文传递
导出
摘要 常染色体显性多囊肾病(autosomal dominant polycystic kidney disease,ADPKD)是全球范围内发病率最高的单基因遗传性肾病,全世界约有1250万ADPKD患者,大约有77%的患者在70岁之前进展至终末期肾病(end-stage renal disease,ESRD),甚至死亡,是ESRD的第4位病因[1-2].其病理特征为肾小管细胞获得异常增殖能力,逐渐形成大小不等的囊肿,囊肿不断增大压迫临近正常肾单位,导致肾脏结构和功能不可逆的损害,最终进入ESRD.ADPKD临床主要表现为高血压、血尿、尿路感染、肾结石、慢性疼痛等.ADPKD是一种系统性疾病,除肾脏外还累及全身多个脏器,常见的肾外表现有多发性肝囊肿、胰腺囊肿、颅内动脉瘤、心脏瓣膜病、结肠憩室等,故其危害严重,为社会和家庭带来了沉重的负担[3].
作者 景颖 梅长林
出处 《中华肾脏病杂志》 CAS CSCD 北大核心 2015年第12期944-947,共4页 Chinese Journal of Nephrology
基金 国家自然科学基金(31371172)
  • 相关文献

参考文献35

  • 1Gabow PA, Johnson AM, Kaehny WD, et al. Factors affecting the progression of renal disease in autosomal- dominant polycystic kidney disease[J]. Kidney Int, 1992, 41(5): 1311- 1319.
  • 2Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease[J]. Lancet, 2007, 369(9569): 1287-1301.
  • 3Tortes VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years[J]. Kidney Int, 2009, 76(2): 149-168.
  • 4Barua M, Cil O, Paterson AD, et al. Family history of renal disease severity predicts the mutated gene in ADPKD[J]. J Am Soc Nephrol, 2009, 20(8): 1833-1838.
  • 5Chapman AB, Devuyst O, Eckardt KU, et al. Autosomal- dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference[J]. Kidney Int, 2015, 88(1): 17-27.
  • 6Su Z, Wang X, Gao X, et al. Excessive activation of the alternative complement pathway in autosomal dominant polycystic kidney disease[J]. J Intern Med, 2014, 276(5): 470- 485.
  • 7Wang X, Zhang S, Liu Y, et al. Targeting of sodium-glucose cotransporters with phlorizin inhibits polycystic kidney disease progression in Han:SPRD rats[J]. Kidney Int, 2013, 84(5): 962- 968.
  • 8薛澄,吴明,付莉莉,张颖慧,王武涛,顾向晨,高翔,梅长林.常染色体显性遗传多囊肾病中JAK2-STAT3通路对补体因子B表达的调控作用[J].中华肾脏病杂志,2014,30(4):304-309. 被引量:3
  • 9Torres VE, Harris PC. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease[J]. J Am Soc Nephrol, 2014, 25(1): 18-32.
  • 10Higashihara E, Torres VE, Chapman AB, et al. Tolvaptan in autosomal dominant polycystic kidney disease: three years" experience[J]. Clin J Am Soc Nephrol, 2011, 6(10): 2499-2507.

二级参考文献19

  • 1Wuthrieh RP, Mei C. Aquaretie treatmen| in polycystie kidney disease[J]. N Engl J Med, 2012, 367: 2440-2442.
  • 2Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease[J]. Lancet, 2007, 369: 1287-1301.
  • 3Torres VE, Harris PC. Polycystic kidney disease: genes, proteins, animal models, disease mechanisms and therapeutic opportunities[J]. J Intern Med, 2007, 261: 17-31.
  • 4Xue C, Dai B, Mei C. lxmg-term treatment with mammalian target of rapamycin inhibitor does not benefit patients with autosomal dominant polycystic kidney disease: a meta-analysis IJ]. Nephron Clin Pract, 2013, 124: 10-16.
  • 5Bhunia AK, Piontek K, Boletta A, et al. PKD1 induces p21 (wafl) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2 IJl. Cell, 2002, 109: 157-168.
  • 6Mitzel DN, Jaramillo R J, Stout- Delgado H, et al. Human metapneumovirus inhibits the IL- 6- induced JAK/STAT3 signalling cascade in airway epithelium[J]. J Gen Virol, 2014, 95: 26-37.
  • 7Lesher AM, Song WC. Review: complement and its regulatory proteins in kidney diseases[J]. Nephrology (Carlton), 2010, 15: 663 -675.
  • 8Burtey S J, Riera M, Font6s M. Overexpression of complement- component genes in Ham SPRD rats a model of polycystic kidney disease[J]. Kidney lnt, 2008, 73: 1324-1325: author reply 1325.
  • 9l,ai X, Bacalla,) RL, Blazer-Yost BL, et al. Characterization of the renal cyst fluid pmteome in autosomal dominant polycystic kidney disease(ADPKD) patients[J]. Proteomics Clin Appl, 2008, 2: 1140-1152.
  • 10Talbot JJ, Shillingford JM, Vasanth S, et al. Polycystin- 1 regulates STAT ac, tivity by a dual mechanism[J]. Prnc Natl Acad Sci U S A, 2011, 108: 7985-7990.

共引文献2

同被引文献39

引证文献6

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部